📊 ANNX Key Takeaways
Is Annexon, Inc. (ANNX) a Good Investment?
Annexon maintains a strong balance sheet with $175.2M in cash and zero debt, providing multi-year operational runway. However, operating losses of $46.1M and worsening net income deterioration of -50.9% YoY indicate accelerating cash burn without near-term revenue, creating execution risk entirely dependent on pipeline success.
Annexon appears to be a pre-revenue biotech with no reported revenue, deep operating losses, and materially negative free cash flow, which makes the fundamentals highly dependent on future clinical and regulatory execution rather than current business performance. The balance sheet is relatively clean, with $139.42M of cash, no long-term debt, and strong liquidity ratios, but the current cash burn of roughly $140M per year implies limited runway without major operating improvement or additional capital.
Annexon, Inc. Key Strengths (ANNX)
- Exceptional cash position of $175.2M with zero debt enabling operational flexibility
- Outstanding liquidity ratios (6.35x current ratio) with minimal leverage and liabilities of only $58.4M
- Strong stockholders' equity of $204.5M providing substantial financial cushion for R&D investment
- Strong liquidity profile with a 4.42x current and quick ratio
- Large cash balance of $139.42M and no long-term debt
- Diluted EPS improved year over year, suggesting some per-share loss moderation
ANNX Stock Risks: Annexon, Inc. Investment Risks
- Accelerating operating losses with net income deteriorating 50.9% YoY and EPS worsening 32.7% YoY
- Pre-revenue clinical-stage company with $46.8M quarterly operating cash burn and no near-term commercialization
- Dilution risk and additional capital raise necessity as cash runway estimated at 3-4 years at current burn rate
- Pipeline success entirely dependent on clinical trial outcomes and regulatory approval with no revenue diversification
- No revenue base, so there is no evidence yet of commercial traction or operating leverage
- Very large annual net loss and negative operating cash flow indicate heavy cash burn
- Cash runway looks tight relative to burn, increasing the risk of future dilution or financing needs
Key Metrics to Watch
- Operating cash burn rate and months of cash runway remaining
- Clinical trial enrollment and efficacy results for lead candidates
- Timing and amount of next capital raise and potential dilution impact
- Quarterly operating cash burn versus cash balance
- Any emergence of revenue and improvement in operating loss trend
Annexon, Inc. (ANNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.35x current ratio provides a solid financial cushion.
ANNX Profit Margin, ROE & Profitability Analysis
ANNX vs Healthcare Sector: How Annexon, Inc. Compares
How Annexon, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Annexon, Inc. Stock Overvalued? ANNX Valuation Analysis 2026
Based on fundamental analysis, Annexon, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Annexon, Inc. Balance Sheet: ANNX Debt, Cash & Liquidity
ANNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Annexon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.01 indicates the company is currently unprofitable.
ANNX Revenue Growth, EPS Growth & YoY Performance
Annexon, Inc. Dividends, Buybacks & Capital Allocation
ANNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Annexon, Inc. (CIK: 0001528115)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANNX
What is the AI rating for ANNX?
Annexon, Inc. (ANNX) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANNX's key strengths?
Claude: Exceptional cash position of $175.2M with zero debt enabling operational flexibility. Outstanding liquidity ratios (6.35x current ratio) with minimal leverage and liabilities of only $58.4M. ChatGPT: Strong liquidity profile with a 4.42x current and quick ratio. Large cash balance of $139.42M and no long-term debt.
What are the risks of investing in ANNX?
Claude: Accelerating operating losses with net income deteriorating 50.9% YoY and EPS worsening 32.7% YoY. Pre-revenue clinical-stage company with $46.8M quarterly operating cash burn and no near-term commercialization. ChatGPT: No revenue base, so there is no evidence yet of commercial traction or operating leverage. Very large annual net loss and negative operating cash flow indicate heavy cash burn.
What is ANNX's revenue and growth?
Annexon, Inc. reported revenue of N/A.
Does ANNX pay dividends?
Annexon, Inc. does not currently pay dividends.
Where can I find ANNX SEC filings?
Official SEC filings for Annexon, Inc. (CIK: 0001528115) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANNX's EPS?
Annexon, Inc. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANNX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Annexon, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ANNX stock overvalued or undervalued?
Valuation metrics for ANNX: ROE of -21.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANNX's AI grade for 2026?
Our dual AI analysis gives Annexon, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANNX's free cash flow?
Annexon, Inc.'s operating cash flow is $-46.8M, with capital expenditures of $0.0.
How does ANNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -21.6% (avg: 15%), current ratio 6.35 (avg: 2).